Stories of Innovation. Data to Back It Up. View the 2024 Impact Report >

Search

Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings

Affinivax, Inc. announces initiation of Phase 1/2 clinical study of ASP3772, its novel pneumococcal MAPS vaccine, in collaboration with Astellas

Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque’s Deep-Primed T Cell Immunotherapies

Axial Biotherapeutics nets $25M for clinical gut-brain axis studies into autism and Parkinson’s

EnClear Therapies Announces Seed Funding and Senior R&D Appointment

How one company thinks unraveling cough can provide a new way to treat pain

LabCentral 2018 Impact Report: Resident Companies Raised the Equivalent of 40% of Early Life Sciences VC Funding in Massachusetts and 6% of U.S. Life Sciences IPOs

Kendall Square launchpad for high-potential life…

Pfizer Opens Call for Proposals for Start-ups to Apply for LabCentral Residency

Bristol Myers-Squibb LabCentral 'Golden Ticket' Submission

#OfficeEnvy: How LabCentral Designs For Scientific Collaboration